This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, S. L.
Right arrow Articles by Berul, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, S. L.
Right arrow Articles by Berul, C. I.
Related Collections
Right arrow Heart & Blood Vessels

PEDIATRICS Vol. 101 No. 6 June 1998, pp. 1053-1056

Proarrhythmia Associated With Cisapride in Children

Received Dec 8, 1997; accepted Mar 19, 1998.

Sharon Laneau Hill*, Juli-anne K. Evangelista*, Anne Marie PizziDagger , Munir MobassalehDagger , David R. Fulton*, and Charles I. Berul*

From the Divisions of * Pediatric Cardiology and Dagger  Pediatric Gastroenterology, Floating Hospital for Children at New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts.

Background.  Cisapride is a prokinetic agent that facilitates gastrointestinal motility and is widely used for the treatment of gastroesophageal reflux disease (GERD) in adults and children. However, reports of ventricular proarrhythmia have been noted in patients taking cisapride, particularly in conjunction with other drugs that may inhibit hepatic metabolism of cisapride via the cytochrome P450 3A4 system.

Objective.  We designed a prospective, blinded study to evaluate the effect of cisapride on ventricular repolarization in children with GERD.

Methods.  We analyzed the electrocardiograms (ECGs) from 35 children (age 0.4 to 18 years, mean 5.2 years) including measurement of the resting QT interval (QTc), JT interval (JTc), as well as QT and JT interlead dispersion markers. Data from these patients were compared with ECGs from a control group of 1000 normal children.

Results.  Eleven (31%) of 35 patients receiving cisapride had a prolonged QTc (>= 450 ms). The JTc was prolonged >= 360 ms in 16 of 35 patients (46%). The mean QTc in the cisapride group was 428 ± 35 ms and mean JTc was 336 ± 35 ms. An increased QT or JT dispersion (>70 ms) was seen in only 3 of 35 children. Of the 11 children with QTc prolongation, 2 had documented torsades de pointes ventricular tachycardia. Both patients were taking cisapride concomitantly with a macrolide antibiotic. All other patients were treated with either cisapride alone or in conjunction with other GERD agents, such as ranitidine or omeprazole.

Conclusions.  Cisapride may cause prolongation of ventricular repolarization in children. There does not appear to be increased heterogeneity of repolarization or delayed depolarization in this small sample. The proarrhythmia may be exacerbated by medications that inhibit cytochrome P450 3A4 hepatic metabolism, overdosage, or mechanisms that result in decreased serum clearance. ECG intervals should be monitored in children maintained on cisapride, particularly when used in combination with other known QT-prolonging medications.

Key words: cisapride, arrhythmia, QT interval, repolarization.




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
M.N. M. N. Obreztchikova, E.A. E. A. Sosunov, A. Plotnikov, E.P. E. P. Anyukhovsky, R. Z. Gainullin, P. Danilo Jr., Z.-H. Yeom, R. B. Robinson, and M. R. Rosen
Developmental changes in IKr and IKs contribute to age-related expression of dofetilide effects on repolarization and proarrhythmia
Cardiovasc Res, August 1, 2003; 59(2): 339 - 350.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. T. Barbey, R. Lazzara, and D. P. Zipes
Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2002; 7(2): 65 - 76.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
B. Darpo
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K70 - K80.
[Abstract] [PDF]


Home page
PediatricsHome page
A. Dubin, M. Kikkert, M. Mirmiran, and R. Ariagno
Cisapride Associated With QTc Prolongation in Very Low Birth Weight Preterm Infants
Pediatrics, June 1, 2001; 107(6): 1313 - 1316.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P.R Rijnbeek, M Witsenburg, E Schrama, J Hess, and J.A Kors
New normal limits for the paediatric electrocardiogram
Eur. Heart J., April 2, 2001; 22(8): 702 - 711.
[Abstract] [PDF]


Home page
PediatricsHome page
R. L. Ariagno, M. A. Kikkert, M. Mirmiran, C. Conrad, and R. B. Baldwin
Cisapride Decreases Gastroesophageal Reflux in Preterm Infants
Pediatrics, April 1, 2001; 107(4): e58 - e58.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
D S Semama, S Bernardini, S Louf, B Laurent-Atthalin, and J-B Gouyon
Effects of cisapride on QTc interval in term neonates
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2001; 84(1): 44F - 46.
[Abstract] [Full Text]


Home page
PediatricsHome page
A. Benatar, A. Feenstra, T. Decraene, and Y. Vandenplas
Effects of Cisapride on Corrected QT Interval, Heart Rate, and Rhythm in Infants Undergoing Polysomnography
Pediatrics, December 1, 2000; 106(6): 85e - 85.
[Abstract] [Full Text]


Home page
PediatricsHome page
J. Ramírez-Mayans, L. M. Garrido-García, A. Huerta-Tecanhuey, P. Gutierrez-Castrellón, R. Cervantes-Bustamante, N. Mata-Rivera, and F. Zárate-Mondragón
Cisapride and QTc Interval in Children
Pediatrics, November 1, 2000; 106(5): 1028 - 1030.
[Abstract] [Full Text]


Home page
PediatricsHome page
V. Khoshoo, D. Edell, and R. Clarke
Effect of Cisapride on the QT Interval in Infants With Gastroesophageal Reflux
Pediatrics, February 1, 2000; 105(2): 24e - 24.
[Abstract] [Full Text]


Home page
Arch. Dis. Child.Home page
S. W JONES and M. WAGSTAFF
Risks and benefits of cisapride
Arch. Dis. Child., June 1, 1999; 80(6): 579i - 579.
[Full Text]


Home page
PediatricsHome page
A. Benatar, A. Feenstra, T. Decraene, Y. Vandenplas;, S. L. Hill, and C. Berul
Cisapride and Proarrhythmia in Childhood
Pediatrics, April 1, 1999; 103(4): 856 - 856.
[Full Text]


Home page
PediatricsHome page
R. M. Ward, J. A. Lemons, and R. A. Molteni
Cisapride: A Survey of the Frequency of Use and Adverse Events in Premature Newborns
Pediatrics, February 1, 1999; 103(2): 469 - 472.
[Abstract] [Full Text]


Home page
Arch. Dis. Child.Home page
A. LANDER and A. DESAI
The risks and benefits of cisapride in premature neonates, infants, and children
Arch. Dis. Child., December 1, 1998; 79(6): 469 - 470.
[Full Text]